EPS for Valeant Pharmaceuticals International, Inc. (VRX) Expected At $0.80

July 22, 2018 - By Rene Reddy

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) LogoInvestors sentiment increased to 1.06 in Q1 2018. Its up 0.09, from 0.97 in 2017Q4. It increased, as 29 investors sold Valeant Pharmaceuticals International, Inc. shares while 90 reduced holdings. 52 funds opened positions while 74 raised stakes. 167.32 million shares or 1.38% less from 169.66 million shares in 2017Q4 were reported.
Rbf Ltd Co stated it has 0.38% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Mackenzie Financial accumulated 671,394 shares. 1832 Asset Mgmt Ltd Partnership reported 270 shares. Wellington Grp Inc Limited Liability Partnership invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Terril Brothers accumulated 113,155 shares. M&R Cap Management owns 200 shares. Vertex One Asset has invested 1.43% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). San Francisco Sentry Inv Group Inc (Ca) stated it has 6,300 shares or 0.03% of all its holdings. Advisory Svcs Network holds 0% of its portfolio in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) for 56 shares. Cibc Asset reported 426,335 shares. Us Natl Bank De holds 0% or 16,364 shares. Boothbay Fund Ltd Limited Liability Company reported 50,000 shares. Wg Shaheen And Dba Whitney And invested in 0% or 900 shares. Brandywine Global Investment Mngmt Limited Liability has invested 0% in Valeant Pharmaceuticals International, Inc. (NYSE:VRX). Cap Ww holds 1.10 million shares or 0% of its portfolio.

Since March 8, 2018, it had 5 insider purchases, and 0 selling transactions for $1.42 million activity. The insider PAPA JOSEPH C bought $481,500. Shares for $218,000 were bought by DE SCHUTTER RICHARD U.

Analysts expect Valeant Pharmaceuticals International, Inc. (NYSE:VRX) to report $0.80 EPS on August, 14.They anticipate $0.25 EPS change or 23.81 % from last quarter’s $1.05 EPS. VRX’s profit would be $279.45 million giving it 7.31 P/E if the $0.80 EPS is correct. After having $0.89 EPS previously, Valeant Pharmaceuticals International, Inc.’s analysts see -10.11 % EPS growth. The stock decreased 3.43% or $0.83 during the last trading session, reaching $23.4. About 6.57 million shares traded. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has risen 73.89% since July 22, 2017 and is uptrending. It has outperformed by 61.32% the S&P500.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Ratings Coverage

Among 13 analysts covering Valeant Pharmaceuticals (NYSE:VRX), 4 have Buy rating, 2 Sell and 7 Hold. Therefore 31% are positive. Valeant Pharmaceuticals had 25 analyst reports since January 24, 2018 according to SRatingsIntel. Barclays Capital upgraded Valeant Pharmaceuticals International, Inc. (NYSE:VRX) on Wednesday, June 6 to “Overweight” rating. The firm has “Hold” rating by Canaccord Genuity given on Monday, February 26. Cantor Fitzgerald maintained the stock with “Buy” rating in Wednesday, February 28 report. On Tuesday, June 5 the stock rating was maintained by H.C. Wainwright with “Hold”. The rating was maintained by Susquehanna with “Hold” on Thursday, March 8. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) earned “Hold” rating by H.C. Wainwright on Thursday, March 15. The stock of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has “Hold” rating given on Monday, May 7 by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Hold” on Tuesday, June 19. The firm has “Buy” rating given on Monday, March 5 by Deutsche Bank. The stock has “Hold” rating by BTIG Research on Tuesday, June 19.

Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device firm worldwide. The company has market cap of $8.17 billion. It operates in three divisions: Bausch + Lomb/International, Branded Rx, and U.S. It has a 3.43 P/E ratio. Diversified Products.

More news for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) were recently published by: Streetinsider.com, which released: “Valeant Pharmaceuticals (VRX) PT Raised to $31 at Mizuho Securities on Xifaxan Growth” on June 29, 2018. Prnewswire.com‘s article titled: “International Ophthalmology and Optometry Devices Market Booming With New Growth Opportunities” and published on July 19, 2018 is yet another important article.

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.